JP2013531058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531058A5 JP2013531058A5 JP2013520221A JP2013520221A JP2013531058A5 JP 2013531058 A5 JP2013531058 A5 JP 2013531058A5 JP 2013520221 A JP2013520221 A JP 2013520221A JP 2013520221 A JP2013520221 A JP 2013520221A JP 2013531058 A5 JP2013531058 A5 JP 2013531058A5
- Authority
- JP
- Japan
- Prior art keywords
- erlotinib
- solvent
- base
- salt
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 33
- 238000000034 method Methods 0.000 claims 32
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 22
- 229960001433 erlotinib Drugs 0.000 claims 22
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 22
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 18
- 239000002904 solvent Substances 0.000 claims 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 10
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 8
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 8
- 229960005073 erlotinib hydrochloride Drugs 0.000 claims 8
- 239000007810 chemical reaction solvent Substances 0.000 claims 7
- 238000002425 crystallisation Methods 0.000 claims 6
- 230000008025 crystallization Effects 0.000 claims 6
- 239000011541 reaction mixture Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical compound NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 claims 2
- ZPJLDMNVDPGZIU-UHFFFAOYSA-N 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline Chemical compound C1=NC(Cl)=C2C=C(OCCOC)C(OCCOC)=CC2=N1 ZPJLDMNVDPGZIU-UHFFFAOYSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 125000005587 carbonate group Chemical group 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 150000004923 Erlotinib derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2112MU2010 | 2010-07-23 | ||
| IN2112/MUM/2010 | 2010-07-23 | ||
| PCT/GB2011/051394 WO2012028861A1 (en) | 2010-07-23 | 2011-07-22 | Pure erlotinib |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093409A Division JP6374436B2 (ja) | 2010-07-23 | 2016-05-06 | 純粋なエルロチニブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531058A JP2013531058A (ja) | 2013-08-01 |
| JP2013531058A5 true JP2013531058A5 (cg-RX-API-DMAC7.html) | 2014-09-11 |
| JP5948597B2 JP5948597B2 (ja) | 2016-07-06 |
Family
ID=44514823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520221A Active JP5948597B2 (ja) | 2010-07-23 | 2011-07-22 | 純粋なエルロチニブ |
| JP2016093409A Expired - Fee Related JP6374436B2 (ja) | 2010-07-23 | 2016-05-06 | 純粋なエルロチニブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093409A Expired - Fee Related JP6374436B2 (ja) | 2010-07-23 | 2016-05-06 | 純粋なエルロチニブ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8952022B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2595629A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5948597B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103124557A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011298167B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2806273A1 (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ628796A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012028861A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012028861A1 (en) * | 2010-07-23 | 2012-03-08 | Generics [Uk] Limited | Pure erlotinib |
| CN103420924B (zh) * | 2012-05-25 | 2016-08-31 | 浙江九洲药业股份有限公司 | 一种盐酸埃罗替尼晶型a的制备方法 |
| WO2014023027A1 (zh) * | 2012-08-10 | 2014-02-13 | 上海创诺医药集团有限公司 | 盐酸埃罗替尼多晶型物及其制备方法 |
| WO2014118112A1 (en) * | 2013-01-29 | 2014-08-07 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
| CN104072427B (zh) * | 2013-03-29 | 2019-05-28 | 江苏豪森药业集团有限公司 | 盐酸厄洛替尼晶型的制备方法 |
| WO2020165672A1 (en) | 2019-02-15 | 2020-08-20 | Shivalik Rasayan Limited | Process for preparation of highly pure fingolimod hydrochloride |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0817775B1 (en) * | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| RS49836B (sr) | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7148231B2 (en) | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
| US7625911B2 (en) | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| US7960545B2 (en) | 2005-11-23 | 2011-06-14 | Natco Pharma Limited | Process for the prepartion of erlotinib |
| US8372856B2 (en) | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
| PT2170844T (pt) | 2007-02-21 | 2016-08-05 | Natco Pharma Ltd | Novos polimorfos de cloridrato de erlotinib e método de preparação |
| US8642758B2 (en) | 2007-04-04 | 2014-02-04 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
| US20090012295A1 (en) | 2007-06-25 | 2009-01-08 | Ales Gavenda | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib |
| ES2492645T3 (es) * | 2007-07-11 | 2014-09-10 | Hetero Drugs Limited | Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib |
| WO2009024989A2 (en) * | 2007-08-17 | 2009-02-26 | Hetero Drugs Limited | A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
| US20090124642A1 (en) * | 2007-08-23 | 2009-05-14 | Augusto Canavesi | Crystalline forms of Erlotinib HCI and formulations thereof |
| TW200925152A (en) | 2007-08-23 | 2009-06-16 | Plus Chemicals S A | Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL |
| KR20110017907A (ko) | 2008-07-07 | 2011-02-22 | 플러스 케미칼스, 에스.에이. | 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형 |
| WO2010040212A1 (en) | 2008-10-08 | 2010-04-15 | Apotex Pharmachem Inc. | Processes for the preparation of erlotinib hydrochloride |
| WO2012028861A1 (en) | 2010-07-23 | 2012-03-08 | Generics [Uk] Limited | Pure erlotinib |
-
2011
- 2011-07-22 WO PCT/GB2011/051394 patent/WO2012028861A1/en not_active Ceased
- 2011-07-22 NZ NZ628796A patent/NZ628796A/en not_active IP Right Cessation
- 2011-07-22 JP JP2013520221A patent/JP5948597B2/ja active Active
- 2011-07-22 CA CA 2806273 patent/CA2806273A1/en not_active Abandoned
- 2011-07-22 NZ NZ606042A patent/NZ606042A/en not_active IP Right Cessation
- 2011-07-22 AU AU2011298167A patent/AU2011298167B2/en not_active Ceased
- 2011-07-22 US US13/811,628 patent/US8952022B2/en active Active
- 2011-07-22 EP EP11741276.7A patent/EP2595629A1/en not_active Withdrawn
- 2011-07-22 CN CN2011800459093A patent/CN103124557A/zh active Pending
-
2015
- 2015-01-06 US US14/590,519 patent/US9340515B2/en active Active
-
2016
- 2016-05-06 JP JP2016093409A patent/JP6374436B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531058A5 (cg-RX-API-DMAC7.html) | ||
| JP2016535081A5 (cg-RX-API-DMAC7.html) | ||
| AR083213A1 (es) | Proceso de preparacion de derivados pirimidinicos, compuestos intermediarios y proceso para prepararlos | |
| UA109883C2 (uk) | Спосіб отримання сполук для застосування як інгібіторів sglt2 | |
| EA201201179A1 (ru) | Способ получения изоксазолиновых производных | |
| JP2017501141A5 (cg-RX-API-DMAC7.html) | ||
| JP2014511367A5 (cg-RX-API-DMAC7.html) | ||
| JP2014507414A5 (cg-RX-API-DMAC7.html) | ||
| AR117002A2 (es) | Proceso para la preparación de inhibidores de quinasa c-fms | |
| RU2016123144A (ru) | Сложноэфирное хиральное соединение (n-замещенный имидазол)-карбоновой кислоты, содержащее простую эфирную боковую цепь, его получение и применение | |
| JP2016517886A5 (cg-RX-API-DMAC7.html) | ||
| WO2009017091A1 (ja) | β－ニトロスチレン化合物の製造方法 | |
| RU2015151359A (ru) | Синтез 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2, 6-диона | |
| JP2014522385A5 (cg-RX-API-DMAC7.html) | ||
| NZ599747A (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives | |
| RU2018130327A (ru) | Улучшенный способ получения осимертиниба (azd9291) или его соли и "анилин-azd9291" или его соли | |
| NZ606042A (en) | Process for the preparation of erlotinib and salts thereof | |
| CN104447547A (zh) | 4-氨基异喹啉-8-甲酸甲酯的合成方法 | |
| RU2019106531A (ru) | Кристалл соли производного хиназолина | |
| JP2022060192A5 (cg-RX-API-DMAC7.html) | ||
| RU2016134404A (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| JP2013503145A5 (cg-RX-API-DMAC7.html) | ||
| US9745264B2 (en) | Method for preparing silodosin and intermediate thereof | |
| RU2012142223A (ru) | Пространственно-затрудненные амины | |
| JP2014196365A5 (cg-RX-API-DMAC7.html) |